Algorithms for menopausal hormone therapy during the period of periand postmenopause. Joint position statement of RSOG RAM, AGE, RAOP experts


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Full Text

Restricted Access

About the authors

- -

References

  1. https://www.worldometers.info/demographics/world-demographics/ Accessed 20 Jan 2021.
  2. Улумбекова Г.Э., Худова И.Ю. Оценка демографического, социального и экономического эффекта при приеме менопаузальной гормональной терапии. ОРГЗДРАВ: новости, мнения, обучение. Вестник ВШОУЗ. 2020; 6(4): 23-53. https://dx.doi.org/10.24411/ 2411-8621-2020-14002.
  3. Turner R.J., Kerber I.J. Eu-estrogenemia, WHI, timing and the "Geripause". Int. Urogynecol. J. Pelvic Floor Dysfunct. 2008; 19(11): 1461-3. https:// dx.doi.org/10.1007/s00192-008-0708-6.
  4. Turner R.J., Kerber I.J. A theory of eu-estrogenemia: a unifying concept. Menopause. 2017; 24(9): 1086-97. https://dx.doi.org/10.1097/ GME.0000000000000895.
  5. Юренева С.S., Дубровина А.В. Преимущества раннего/своевременного старта менопаузальной гормональной терапии с позиции теории эуэстрогенемии. Российский вестник акушера-гинеколога. 2018; 18(5): 49-55.
  6. Miller V.M., Kling J.M., Files J.A., Joyner M.J., Kapoor E., Moyer A.M. et al. What’s in a name: are menopausal ‘‘hot flashes’’ a symptom of menopause or a manifestation of neurovascular dysregulation? Menopause. 2018; 25(6): 700-3. https://dx.doi.org/10.1097/GME.0000000000001065.
  7. Tepper P.G., Brooks M.M., Randolph J.F. Jr., Crawford S.L., ElKhoudary S.R., Gold E.B. et al. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause. 2016; 23(10): 1067-74. https://dx.doi. org/10.1097/GME.0000000000000676.
  8. Baber R.J., Panay N., Fenton A.; the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/10.3109/13697 137.2015.1129166.
  9. Clarkson T.B. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause. 2018; 25(11): 1262-74. https://dx.doi.org/10.1097/GME.0000000000001228.
  10. Hodis H.N., Mack W.J., Shoupe D., Azen S.P., Stanczyk F.Z., Hwang-Levine J. et al. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause. 2015; 22 (4): 391-401. https://dx.doi.org/10.1097/ GME.0000000000000343.
  11. Bild D.E., Bluemke D.A., Burke G.L., Detrano R., Diez Roux A.V., Folsom A.R. et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am. J. Epidemiol. 2002; 156 (9): 871-81. https://dx.doi.org/10.1093/aje/ kwf113.
  12. Manson J.E., Chlebowski R.T., Stefanick M.L., Aragaki A.K., Rossouw J.E., Prentice R.L. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310(13): 1353-68. https:// dx.doi.org/10.1001/jama.2013.278040.
  13. Roehm E. A reappraisal of Women’s Health Initiative Estrogen-Alone Trial: long-term outcomes in women 50-59 years of age. Obstet. Gynecol. Int. 2015; 2015: 713295.
  14. Panay N., Anderson R.A., Nappi R.E., Vincent AJ., Vujovic S., Webber L., Wolfman W. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020; 23(5): 426-46. https://dx.doi.org/ 10.1080/13697137.2020.1804547.
  15. Радзинский В.Е., ред. Очерки эндокринной гинекологии. М.: Медиабюро Статус Презенс; 2020. 576с. ISBN 978-5-907218-05-5.
  16. Инструкция по медицинскому применению препарата Фемостон® 1 от 08.10.2019. [Instruction on medical use Femoston® 1 from 08.10.2019 (in Russian)].
  17. Инструкция по медицинскому применению препарата Фемостон® 2 от 14.10.2019. [Instruction on medical use Femoston® 2 from 14.10.2019. (in Russian)].
  18. Инструкция по медицинскому применению препарата Фемостон® мини от 28.05.2019. [Instruction on medical use Femoston® mini from 28.05.2019. (in Russian)].
  19. Инструкция по медицинскому применению препарата Фемостон® конти от 10.10.2019. [Instruction on medical use Femoston® conti from 10.10.2019. (in Russian)].
  20. Australian Menopause Society. Available at: https://www.menopause.org.au/ hp/management/early-menopause. Accessed 20 Jan 2021.
  21. Appendix 6B - Guidance on management of the menopause in primary care. Available at: https://www.fifeadtc.scot.nhs.uk/formulary/6-endocrine/ appendix-6b-management-of-menopause-in-primary-care.aspx.
  22. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017; 24(7): 728-53. https://dx.doi.org/10.1097/ GME.0000000000000921.
  23. Tsiligiannis S., Wick-Urban B.C., van der Stam J., Stevenson J.C. Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms. Maturitas. 2020; 139: 20-6. https://dx.doi.org/10.1016/j.maturitas.2020.05.002.
  24. Munro M.G.; Southern California Permanente Medical Group’s Abnormal Uterine Bleeding Working Group. Investigation ofwomen with postmenopausal uterine bleeding: clinical practice recommendations. Perm. J. 2014; 18(1): 55-70. https://dx.doi.org/10.7812/TPP/13-072.
  25. Carugno J. Clinical management of vaginal bleeding in postmenopausal women, Climacteric. 2020; 23(4): 343-9. https://dx.doi.org/10.1080/ 13697137.2020.1739642.
  26. Clarke M.A., Long B.J., Del Mar Morillo A., Arbyn M., Bakkum-Gamez J.N., Wentzensen N. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern. Med. 2018; 178(9): 1210-22. https://dx.doi.org/10.1001/ jamainternmed.2018.2820.
  27. Bengtsen M.B., Veres K., Norgaard M. First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study. Br. J. Cancer. 2020; 122(3): 445-51. https://dx.doi.org/10.1038/ s41416-019-0668-2.
  28. Dave F.G. Laiyemo R., Adedipe T. Unscheduled bleeding with hormone replacement therapy. Obstetrician Gynaecologist. 2019; 21(2): 95-101. https:// dx.doi.org/10.1111/tog.12553.
  29. Sathiyathasan S., Kannappar J., Lou Y.Y. Unscheduled bleeding on HRT - do we always need to investigate for endometrial pathology? Int. J. Reprod. Contracept. Obstet. Gynecol. 2017; 6(10): 4174-8. https://dx.doi.org/10.18203/2320-1770. ijrcog20174391.
  30. de Medeiros S.F., Yamamoto M.M., Barbosa J.S. Abnormal bleeding during menopause hormone therapy: insights for clinical management. Clin. Med. Insights Womens Health. 2013; 6: 13-24. https://dx.doi.org/10.4137/CMWH.S10483.
  31. https://www.menopause-russia.org/news/primite-uchastie-vo-vserossiyskom-anketirovanii-po-naznacheniyu-i-primeneniyu-mgt/ Accessed 24.02.2021.
  32. Применение гормональных пероральных контрацептивов в России. [Use of hormonal oral contraceptives in Russia] Source: IQVIA, Ex-manufacturer prices in USD (ER=69), Standard units; Internal data: ADS SOP published.
  33. FSRH Clinical Guideline Combined Hormonal Contraception (January 2019, Amended November 2020). Available at: https://www.fsrh.org/standards-and-guidance/documents/combined-hormonal-contraception/ Accessed 20 Jan 2021.
  34. WHO. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015.
  35. Fruzzetti F., Paoletti A.M., Fidecicchi T., Posar G., Giannini R., Gambacciani M. Contraception with estradiol valerate and dienogest: adherence to the method. Open Access J. Contracept. 2019; 10: 1-6. https://dx.doi.org/10.2147/OAJC.S204655.
  36. Australian Menopause Society https://www.menopause.org.au/hp/management/ treatment-options (Access date 20 Jan 2021).
  37. NICE guideline Menopause: diagnosis and management (NG23, published Nov 2015). Available at: nice.org.uk/guidance/NG23. Accessed 20 Jan 2021.
  38. Anagnostis P., Bitzer J., Cano A., Ceausu I., Chedraui P., Durmusoglu F. et al. Menopause symptom management in women with dyslipidemias: an EMAS clinical guide. Maturitas. 2020; 135: 82-88. https://dx.doi.org/10.1016/j. maturitas.2020.03.007.
  39. Slopien R., Wender-Ozegowska E., Rogowicz-Frontczak A., Meczekalski B., Zozulinska-Ziolkiewicz D., Jaremek J.D. et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018; 117: 6-10. https://dx.doi.org/10.1016/j.maturitas.2018.08.009.
  40. Kuh D., Cooper R., Moore A., Richards M., Hardy R. Age at menopause and lifetime cognition: Findings from a British birth cohort study. Neurology. 2018; 90(19): e1673-e1681. https://dx.doi.org/10.1212/ WNL.0000000000005486.
  41. de Villiers T.J., Gass M.L., Haines C.J., Hall J.E., Lobo R.A., Pierroz D.D., Rees M. Global consensus statement on menopausal hormone therapy. Climacteric. 2013; 16(2): 203-4. https://dx.doi.org/10.3109/13697137.2013.771520.
  42. Ettinger B. Effect of the Women’s Health Initiative on women’s decisions to discontinue postmenopausal hormone therapy. Obstet. Gynecol. 2003; 102(6): 1225-32. https://dx.doi.org/10.1016/j.obstetgynecol.2003.08.007.
  43. Crawford S.L., Crandall C.J., Derby C.A., El Khoudary S.R., Waetjen L.E., Fischer M., Joffe H. Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative Study Results. Menopause. 2018; 26(6): 588-97. https://dx.doi.org/10.1097/GME.0000000000001282.
  44. Chlebowski R.R., Anderson G.G. Changing concepts: menopausal hormone therapy and breast cancer. J. Natl. Cancer Inst. 2012; 104: 517-27. https:// dx.doi.org/10.1093/jnci/djs014.
  45. Fournier A., Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. 2008; 107(1): 103-11. https://dx.doi. org/10.1007/s10549-007-9523-x.
  46. Vinogradova Y, Coupland C., Hippisley-Cox Ju. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020; 371: m3873. https://dx.doi. org/10.1136/bmj.m3873.
  47. Telli M.L., Gradishar WJ, Ward J.H. NCCN Guidelines updates: breast cancer. J. Natl. Compr. Canc. Netw. 2019; 17(5.5): 552-5. https://dx.doi.org/ 10.6004/jnccn.2019.5006.
  48. Torrens J.I., Sutton-Tyrrell K., Zhao X., Matthews K., Brockwell S., Sowers M, Santoro N. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in mid-life women. Menopause. 2009; 16(2): 257-64. https://dx.doi.org/10.1097/ gme.0b013e318185e249.
  49. Markopoulos M.C., Kassi E., Alexandraki K.I., Mastorakos G., Kaltsas G. Hyperandrogenism after menopause. Eur. J. Endocrinol. 2015; 172(2): R79-91. https://dx.doi.org/10.1530/EJE-14-0468.
  50. Wierman M.E., Arlt W., Basson R., Davis S.R., Miller K.K., Murad M.H. et al. Androgen therapy in women: A reappraisal: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2014; 99(10): 3489-510. https:// dx.doi.org/10.1210/jc.2014-2260.
  51. Дубровина С.О. Рациональный подход к гормональной терапии у женщин старше 40 лет. Акушерство и гинекология. 2019; 7:112-16. https:// dx.doi.org/10.18565/aig.2019.7.112-116

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies